Anterior endoderm cells and methods of production
Disclosed herein are cell cultures comprising PDX1-positive endoderm cells and methods of producing the same. Also disclosed herein are cell populations comprising substantially purified PDX1-positive endoderm cells as well as methods for enriching, isolating and purifying PDX1-positive endoderm cells from other cell types. Methods of identifying differentiation factors capable of promoting the differentiation of endoderm cells, such as PDX1-positive foregut endoderm cells and PDX1-negative definitive endoderm cells, are also disclosed.
1. An in vitro method for producing human anterior foregut endoderm cells, comprising:
differentiating human pluripotent stem cells to definitive endoderm cells, and
contacting the definitive endoderm cells with an effective amount of a retinoid to produce human anterior foregut endoderm cells.
2. The in vitro method of claim 1 , wherein the retinoid is retinoic acid (RA).
3. The in vitro method of claim 2 , wherein the RA is provided to the population of human definitive endoderm cells at a concentration of about 1 μM.
4. The in vitro method of claim 1 , wherein the human anterior foregut endoderm cells express HOXA3.
5. An in vitro method for producing human midgut endoderm cells, comprising:
differentiating human pluripotent stem cells to definitive endoderm cells, and
contacting the definitive endoderm cells with an effective amount of a retinoid to produce human midgut endoderm cells.
6. The in vitro method of claim 5 , wherein the retinoid is RA.
7. The in vitro method of claim 6 , wherein the RA is provided to the population of human definitive endoderm cells at a concentration of about 0.2 μM.
8. An in vitro method for producing human hindgut endoderm cells, comprising:
differentiating human pluripotent stem cells to definitive endoderm cells, and
contacting the definitive endoderm cells with an effective amount of a retinoid to produce human hindgut endoderm cells.
9. The in vitro method of claim 8 , wherein the retinoid is RA.
10. The in vitro method of claim 9 , wherein the RA is provided to the population of human definitive endoderm cells at a concentration of at least 0.04 μM.
11. An in vitro method for producing anterior foregut endoderm cells, midgut endoderm cells and/or hindgut endoderm cells, comprising:
differentiating human pluripotent stem cells to definitive endoderm cells, and
contacting the definitive endoderm cell population with a retinoid in an amount sufficient to produce the human anterior foregut endoderm cells, midgut endoderm cells and/or human hindgut endoderm cells.
12. The in vitro method of claim 11 , wherein the retinoid is RA.
13. The in vitro method of claim 12 , wherein the RA is provided to the human definitive endoderm cell population at a concentration from about 0.04 μM to about 1 μM.
14. The in vitro method of claim 12 , wherein the RA is provided to the human definitive endoderm cell population at concentration of about 0.04 μM and human hindgut endoderm cells are produced.
15. The in vitro method of claim 12 , wherein the RA is provided to the human definitive endoderm cell population at a concentration of about 0.2 μM and human midgut endoderm cells are produced.
16. The in vitro method of claim 12 , wherein the RA is provided to the human definitive endoderm cell population at a concentration of about 1 μM and human anterior foregut endoderm cells are produced.
17. The in vitro method of claim 14 , wherein the human hindgut endoderm cells express HOXA13.
18. The in vitro method of claim 15 , wherein the human midgut endoderm cells express HOXC6.
19. The in vitro method of claim 15 , wherein the human midgut endoderm cells express CDX1.
20. The in vitro method of claim 16 , wherein the human anterior foregut endoderm cells express HOXA3.